Citigroup says big pharma preferred by foreign investors as China reopens, appetite for pre-revenue biotech firms wanes

Source: China – South China Morning PostBig Chinese pharmaceutical firms with a track record of profits will be key beneficiaries of China reopening, with pre-revenue biotechnology companies falling out of favour, Citigroup says.Read More